Application of a PIP4K2A splicing variant in liver cancer tissue

By detecting PIP4K2A splicing variants in liver cancer tissues, the shortcomings in early diagnosis and treatment of liver cancer are solved, effective diagnosis and prognosis evaluation of liver cancer are achieved, and the prognosis of liver cancer is improved by reducing its activity and expression adjuvant treatment.

CN116004833BActive Publication Date: 2024-11-26CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310059552.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-16
Publication Date
2024-11-26
Estimated Expiration
2043-01-16

AI Technical Summary

Technical Problem

There is a lack of effective early diagnosis methods and early treatment intervention methods in the prior art, resulting in poor prognosis of primary liver cancer.

Method used

Using PIP4K2A splicing variants in liver cancer tissues as biomarkers, provides diagnostic and prognostic assessments by detecting their expression levels and concentrations, and assists in treatment by reducing their activity and expression levels.

Benefits of technology

By detecting the presence and expression of PIP4K2A splicing variants, the existence of liver cancer can be effectively judged and the prognosis can be guided, and the proliferation and metastasis of liver cancer cells can be promoted, which provides new methods for early diagnosis and treatment, and improves the prognosis of liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116004833B_ABST
    Figure CN116004833B_ABST
Patent Text Reader

Abstract

The present invention provides an application of a PIP4K2A splicing variant in liver cancer tissue. The functions of the product are at least one of 1)-2): 1) diagnosis or auxiliary diagnosis of liver cancer; 2) liver cancer prognosis assessment; the nucleotide sequence of the PIP4K2A splicing variant is shown in SEQ ID NO.1. The splicing variant PIP4K2A-S can promote the proliferation and metastasis of liver cancer cells, and can promote the growth and metastasis of nude mouse liver orthotopic transplanted tumors, can be used as a diagnostic marker for liver cancer, and has a high guiding significance for judging the prognosis of liver cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biopharmaceutical technology, and in particular to an application of a PIP4K2A splicing variant in liver cancer tissue. Background Art

[0002] Alternative splicing (AS) can edit a single pre-mRNA molecule and produce different mature mRNAs in eukaryotes. These transcript variants can subsequently produce proteins with different structures and biological functions. Therefore, alternative splicing is an important mechanism for post-transcriptional regulation of gene expression and plays a vital role in the diversity of transcriptomes and encoded proteins. Recent high-throughput sequencing studies have shown that more than 95% of genes undergo alternative splicing and produce at least two alternative pre-mRNA isoforms. Abnormal alternative splicing events may be associated with a variety of diseases, especially in the occurrence, development, metastasis and drug resistance of cancer. Alternative splicing events can be used as biomarkers for diagnosis or prognosis, as well as for the development of therapeutic targets for cancer.

[0003] Primary liver cancer ranks fourth in the incidence of malignant tumors in my country, and ranks second in mortality, seriously threatening the lives and health of the Chinese people. Hepatocellular carcinoma (HCC) (hereinafter referred to as liver cancer) is the most common liver cancer in adults, accounting for about 75%-85% of primary liver cancer clinically. The liver has rich blood supply, and early metastasis and postoperative recurrence are the main factors for the poor prognosis of liver cancer. According to statistics, the 5-year survival rate of liver cancer is only 14.1%. The fundamental reason for the poor prognosis of liver cancer is that the early onset of liver cancer is hidden, and there is a lack of effective early diagnosis methods and early treatment intervention methods.

[0004] The PIP4K2A (phosphatidylinositol-5-phosphate 4-kinase 2α) gene is 179.7Kb in length and includes 10 exons. The PIP4K2A cDNA is 3.8kb. The PIP4K2A protein consists of 406 amino acids, has a molecular weight of 53kDa, and has a conserved phosphatidylinositol phosphate kinase (PIPK) domain in the C-terminal region. PIP4K2A belongs to the PIP kinase type II, which also includes PIP4K2B and PIP4K2C. It was originally identified in erythrocytes and is highly expressed in peripheral blood cells. The main function of this protein family is to recognize and phosphorylate phosphatidylinositol (PtdIns) 5P and synthesize phosphatidylinositol-4,5-bisphosphate (PtdIns (4,5) P2). Phosphatidylinositol-4,5-bisphosphate is an important precursor in phosphoinositide signal transduction and can directly regulate the activity of signal transduction proteins and cell processes. Recent studies have shown that PIP4K2A is involved in the regulation of important biological processes of malignant phenotypes, including cell proliferation, clone formation, and survival. However, there are no reports on the relationship between PIP4K2A splicing variants and liver cancer. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides an application of a PIP4K2A splicing variant in liver cancer tissue, which solves the problem of the lack of effective early diagnosis methods and early treatment intervention means for liver cancer in the prior art.

[0006] In one aspect, the present invention provides a use of a PIP4K2A splicing variant as a biomarker in the preparation of a product, wherein the function of the product is at least one of 1)-2):

[0007] 1) Diagnosis or auxiliary diagnosis of liver cancer;

[0008] 2) Prognosis assessment of liver cancer;

[0009] The nucleotide sequence of the PIP4K2A splice variant is shown in SEQ ID NO.1.

[0010] In another aspect, the present invention provides the use of a substance for detecting a splicing variant of PIP4K2A in preparing a product, wherein the function of the product is at least one of 1)-2):

[0011] 1) Diagnosis or auxiliary diagnosis of liver cancer;

[0012] 2) Prognosis assessment of liver cancer;

[0013] The nucleotide sequence of the PIP4K2A splice variant is shown in SEQ ID NO.1.

[0014] Furthermore, the substance for detecting a PIP4K2A splicing variant includes a substance for detecting an expression amount of a PIP4K2A splicing variant and / or a substance for detecting a concentration of a PIP4K2A splicing variant.

[0015] Furthermore, when the expression level and / or concentration of the PIP4K2A splicing variant in the tissue to be detected is higher than that in the control normal tissue, the tissue to be detected is liver cancer tissue; and the control normal tissue is adjacent to the cancer tissue.

[0016] Further, the substance for detecting the PIP4K2A splicing variant includes a primer pair, and the nucleotide sequence of the primer pair is as follows:

[0017] Upstream primer P1: 5′-CAAAAATAAAGGTGGACAATC-3′;

[0018] Downstream primer P2: 5′-AGACAAACGGTGGCTGAA-3′.

[0019] In another aspect, the present invention provides the use of a substance that reduces the activity and / or expression of a splicing variant of PIP4K2A in the preparation of a product, wherein the function of the product is at least one of 1)-2):

[0020] 1) Treatment or adjuvant treatment of liver cancer;

[0021] 2) Treatment or adjuvant treatment of lung metastasis of liver cancer;

[0022] The nucleotide sequence of the PIP4K2A splice variant is shown in SEQ ID NO.1.

[0023] In another aspect, the present invention provides the use of a PIP4K2A splice variant protein as a biomarker in the preparation of a product, wherein the function of the product is at least one of 1)-2):

[0024] 1) Diagnosis or auxiliary diagnosis of liver cancer;

[0025] 2) Prognosis assessment of liver cancer;

[0026] The amino acid sequence of the PIP4K2A splice variant protein is shown in SEQ ID NO.2.

[0027] In another aspect, the present invention provides the use of a substance for detecting a splice variant protein of PIP4K2A in the preparation of a product, wherein the function of the product is at least one of 1)-2):

[0028] 1) Diagnosis or auxiliary diagnosis of liver cancer;

[0029] 2) Prognosis assessment of liver cancer;

[0030] The amino acid sequence of the PIP4K2A splice variant protein is shown in SEQ ID NO.2.

[0031] In another aspect, the present invention provides the use of a substance that reduces the activity and / or expression of a PIP4K2A splicing variant protein in the preparation of a product, wherein the function of the product is at least one of 1)-2):

[0032] 1) Treatment or adjuvant treatment of liver cancer;

[0033] 2) Treatment or adjuvant treatment of lung metastasis of liver cancer;

[0034] The amino acid sequence of the PIP4K2A splice variant protein is shown in SEQ ID NO.2.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] The present invention reversely transcribes RNA extracted from liver cancer tissue, and performs PCR amplification reaction on the reverse transcribed product to obtain a novel splicing variant PIP4K2A-S; experiments show that the novel splicing variant PIP4K2A-S can promote the proliferation and metastasis of liver cancer cells, and can promote the growth and metastasis of orthotopic transplanted tumors in the liver of nude mice. The experimental results show that PIP4K2A-S can be used as a diagnostic marker for liver cancer. Therefore, detecting whether the splicing variant PIP4K2A-S exists in the tissues of liver cancer patients has a high guiding significance for judging the prognosis of liver cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is the gel electrophoresis diagram of the PIP4K2A-S amplification product in Example 1 of the present invention.

[0038] Figure 2 This is a diagram of a CCK-8 cell proliferation test of PLC / PRF / 5 and MHCC-97H cells overexpressing PIP4K2A-L or PIP4K2A-S in Example 2 of the present invention.

[0039] Figure 3 This is a graph showing the ability of PIP4K2A-S to promote the migration of liver cancer cells PLC / PRF / 5 and MHCC-97H cells in Example 2 of the present invention.

[0040] Figure 4 This is a diagram showing the effect of PIP4K2A-S on tumor growth in Example 3 of the present invention.

[0041] Figure 5 This is a diagram showing the effect of PIP4K2A-S on lung metastasis of liver cancer cells in nude mice in Example 3 of the present invention. DETAILED DESCRIPTION

[0042] The technical scheme in the present invention is further described below in conjunction with the accompanying drawings and Examples. The following examples further illustrate the content of the present invention, but should not be construed as limiting the present invention. Without departing from the spirit and substance of the present invention, the modification or replacement of the inventive method, steps or conditions, all belong to the scope of the present invention. If not specifically indicated, the technical means used in the examples are conventional means well known to those skilled in the art.

[0043] Example 1 PIP4K2A splice variant cloning

[0044] 1. Extraction of tissue RNA and cDNA synthesis

[0045] Liver cancer tissues and corresponding adjacent tissues from patients with clinical liver cancer were collected as normal controls. All patients had received local radiotherapy, chemotherapy, or endocrine therapy before surgery. All pathologies were confirmed by postoperative pathology. RNA was extracted from liver cancer tissues and adjacent tissues according to the Trizol kit operating instructions. cDNA was synthesized using a reverse transcription kit.

[0046] 2. Amplification of PIP4K2A splice variants

[0047] Primers were designed based on the PIP4K2A gene cDNA sequence in the GenBank database.

[0048] Upstream primer P1: 5′-CAAAAATAAAGGTGGACAATC-3′;

[0049] Downstream primer P2: 5′-AGACAAACGGTGGCTGAA-3′.

[0050] PCR amplification was performed using cDNA from liver cancer tissue and paracancerous tissue as templates. The PCR reaction was performed according to the kit instructions. The PCR reaction system was (upstream primer: 1ul downstream primer: 1ul HS (Primestar): 0.5ul dNTP Mixture: 2ul 5X Primestar Buffur: 5ul template: 2ul enzyme-free water: 13.5ul)), PCR reaction parameters are (PIP4K2A-L: 98℃5min; 98℃30s, 55℃ (cycle decreases 1℃) 15s, 72℃50s, 5 cycles; 98℃30s, 52℃15s, 72℃50s, 30 cycles; 72℃5min; 4℃hold. PIP4K2A-S: 98℃5min; 98℃30s, 55℃ (cycle decreases 1℃) 15s, 72℃30s, 5 cycles; 98℃30s, 52℃15s, 72℃30s, 3 cycles; 72℃5min; 4℃hold.). Agarose gel electrophoresis detected 2 amplification product bands. The results are as follows Figure 1 As shown, N represents paracancerous tissue, and T represents PCR product of liver cancer tissue. 407bp is a partial sequence of the conventional wild-type PIP4K2A-L transcript, and 254bp is a partial sequence of the abnormal splicing variant transcript PIP4K2A-S. The target fragment was purified using a PCR product purification kit, and then the target fragment was connected to the T vector. The ligation product was transformed into JM109 Escherichia coli, and the positive clones were selected for expansion and culture. The plasmids were separated and purified according to the instructions of the small plasmid extraction kit. The cloned plasmids were sent to Shanghai Yingjun Biotechnology Co., Ltd. for nucleic acid sequence determination. The obtained sequence was analyzed using NCBI GenBank database software, and the sequencing results showed that exon 5 was missing. The nucleotide sequence of exon 5 is shown in SEQ ID NO.4, with a size of 153bp.

[0051] The nucleotide sequence of the conventional wild-type transcript PIP4K2A-L is shown in SEQ ID NO.3, with a size of 1221 bp. The nucleotide sequence of the splice variant PIP4K2A-S is shown in SEQ ID NO.1, with a size of 1068 bp; the amino acid sequence of the splice variant PIP4K2A-S protein is shown in SEQ ID NO.2.

[0052] Example 2 Effect of PIP4K2A-S on the proliferation and migration abilities of liver cancer cells

[0053] 1. Construction of recombinant adenovirus

[0054] Using pAdEasy-1 as the viral backbone plasmid and pAdTrack-TO4 as the shuttle plasmid, recombinant adenovirus AdPIP4K2A-L containing PIP4K2A-L and recombinant adenovirus AdPIP4K2A-S containing PIP4K2A-S were constructed, and a control group AdGFP was set up.

[0055] 2. AdPIP4K2A-L, AdPIP4K2A-S and AdGFP were transfected into liver cancer cells PLC / PRF / 5 and MHCC-97H respectively, and the cell proliferation ability was detected by CCK-8 assay. Figure 2 The Transwell assay was used to detect cell migration ability. Figure 3 shown.

[0056] The results showed that compared with the PIP4K2A-L group, overexpression of PIP4K2A-S significantly accelerated the cell growth rate at 96h, and the difference was statistically significant. Compared with the PIP4K2A-L group, overexpression of PIP4K2A-S significantly promoted the migration of liver cancer cells, and the difference was statistically significant (repeated measures analysis of variance).

[0057] Example 4 PIP4K2A-S promotes the growth of orthotopic liver transplanted tumors and lung metastasis in nude mice

[0058] After 24 h of infection of hepatoma cell line MHCC-97H with recombinant adenovirus AdPIP4K2A-L, AdPIP4K2A-S and AdGFP, the above cells were injected into the left lobe of nude mice liver in situ with 0.1 mL (1×10 6 The mice were killed after 8 weeks, and the tumor nodules in the liver of nude mice were observed with naked eyes. The results are shown in Figure 4.

[0059] The lung tissues of the nude mice were taken out and fixed in 10% neutral formalin solution. HE staining was performed to further clarify the nature of the nodules and observe the distribution of the tumor in the lungs. Figure 5 shown.

[0060] The results showed that compared with the control group, the liver tumors in the PIP4K2A-S overexpression group were larger and more numerous. Multiple obvious metastatic foci formed in the lungs of nude mice in the PIP4K2A-S overexpression group (accounting for 6 / 6); only one nude mouse in the PIP4K2A-L overexpression group had metastatic nodules (4 / 6), while no obvious metastatic foci were found in the GFP control group (3 / 6), and the difference was statistically significant (P<0.05). The results showed that overexpression of PIP4K2A-S can promote the formation of metastatic tumors in nude mice.

[0061] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. Use of a PIP4K2A splicing variant as a biomarker in the preparation of a product for diagnosing or assisting in the diagnosis of liver cancer, wherein the nucleotide sequence of the PIP4K2A splicing variant is shown in SEQ ID NO.

1.

2. Use of a substance for detecting a PIP4K2A splicing variant in the preparation of a product for diagnosing or assisting in the diagnosis of liver cancer, wherein the nucleotide sequence of the PIP4K2A splicing variant is shown in SEQ ID NO.

1.

3. The use according to claim 2, characterized in that: The substance for detecting PIP4K2A splicing variants includes a substance for detecting the expression amount of PIP4K2A splicing variants and / or a substance for detecting the concentration of PIP4K2A splicing variants.

4. The use according to claim 3, characterized in that: When the expression level and / or concentration of the PIP4K2A splicing variant in the tissue to be detected is higher than that in the control normal tissue, the tissue to be detected is liver cancer tissue; and the control normal tissue is adjacent to the cancer tissue.

5. The use according to claim 2, characterized in that: The substance for detecting PIP4K2A splicing variants includes a primer pair, and the nucleotide sequence of the primer pair is as follows: Upstream primer P1: 5′-CAAAAATAAAGGTGGACAATC-3′; Downstream primer P2: 5′-AGACAAACGGTGGCTGAA-3′.